The effect of growth hormone on the metabolome of follicular fluid in patients with diminished ovarian reserve

Reproductive Biology and Endocrinology

Research

Fang Wang¹  Shan Hu Gao²  Yang Yang³  Zhi Yuan⁴  Hongliang Yi⁵  Shen Zhang⁵  Heng Zou⁵  Huijia Chen⁵  Chengguang Sun⁵  Ting-li Han⁶  Fan He⁷  Lina Hu⁷ 

[1] Department of Reproduction and Infertility, Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, 611731, Chengdu, China;Mass Spectrometry Centre of Maternal-Fetal Medicine, Chongqing Medical University, 400010, Chongqing, China;Obstetrics Department, The First Affiliated Hospital of Chongqing Medical University, 400042, Chongqing, China;The Center for Reproductive Medicine, Obstetrics and Gynecology Department, The Second Affiliated Hospital of Chongqing Medical University, 400010, Chongqing, China;The Center for Reproductive Medicine, Obstetrics and Gynecology Department, The Second Affiliated Hospital of Chongqing Medical University, 400010, Chongqing, China;Joint International Research Lab for Reproduction and Development, Ministry of Education, Chongqing Medical University, 400010, Chongqing, China;The Center for Reproductive Medicine, Obstetrics and Gynecology Department, The Second Affiliated Hospital of Chongqing Medical University, 400010, Chongqing, China;Joint International Research Lab for Reproduction and Development, Ministry of Education, Chongqing Medical University, 400010, Chongqing, China;Mass Spectrometry Centre of Maternal-Fetal Medicine, Chongqing Medical University, 400010, Chongqing, China;The Center for Reproductive Medicine, Obstetrics and Gynecology Department, The Second Affiliated Hospital of Chongqing Medical University, 400010, Chongqing, China;Joint International Research Lab for Reproduction and Development, Ministry of Education, Chongqing Medical University, 400010, Chongqing, China;Reproduction and Stem Cell Therapy Research Center of Chongqing, 400010, Chongqing, China;

关键词: Growth hormone;    Diminished ovarian reserve;    Follicular fluid;    Metabolomics;    Gas chromatograph-mass spectrometry;   

DOI  :  10.1186/s12958-023-01073-x

 received in 2022-05-18, accepted in 2023-02-14,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundIncreasing evidence supports that the co-treatment with growth hormone (GH) enhances ovarian response and oocyte quality during controlled ovarian stimulation (COS) in patients with diminished ovarian reserve (DOR). The composition of follicular fluid (FF) plays an essential role in oocyte development and mirrors the communication occurring between the oocyte and follicular microenvironment. However, the effect of GH on the FF metabolome remains unclear.MethodsThis prospective observational study recruited DOR patients undergoing in vitro fertilization (IVF) cycles with minimal stimulation protocol for COS. Each patient receiving GH co-treatment was matched to a patient without GH co-treatment by propensity score matching. The FF was collected after isolating oocytes and assayed by gas chromatograph-mass spectrometry (GC-MS) metabolomics. The Pearson correlation was performed to evaluate the relationship between the number of oocytes retrieved and the levels of differential metabolites. The KEGG database was used to map differential metabolites onto various metabolic pathways.ResultsOne hundred thirty-four FF metabolites were identified by GC-MS metabolomics. Twenty-four metabolites, including glutathione, itaconic acid and S-adenosylmethionin (SAM) showed significant differences between the GH and control groups (p-value < 0.05 and q-value < 0.1). In addition, the number of oocytes retrieved was significantly higher in the GH group compared to the control group (3 vs 2, p = 0.04) and correlated with the levels of five differential metabolites. Among them, the levels of antioxidant metabolite itaconic acid were upregulated by GH administration, while SAM levels were downregulated.ConclusionsThe co-treatment with GH during COS may improve oocyte development by altering FF metabolite profiles in DOR patients. However, given the downregulation of SAM, a regulator of genomic imprinting, the potential risk of imprinting disturbances should not be neglected.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 4

Fig. 2

Fig. 5

Fig. 4

42004_2023_824_Taba_HTML.png

Fig. 3